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a-MSH inhibits induction of C/EBPb-DNA binding activity a-Melanocyte–stimulating hormone (a-MSH) is a pro-
and NOS2 gene transcription in macrophages. opiomelanocortin–derived 13 amino acid peptide released
Background. a-Melanocyte–stimulating hormone (a-MSH) by the pituitary gland and immunocompetent cells that
is an endogenous tridecapeptide that exerts anti-inflammatory
exerts broad anti-inflammatory actions in mammals [1].actions and abrogates postischemic renal injury in rodents.
Concentrations of this neuropeptide increase locally ata-MSH inhibits lipopolysaccharide (LPS)-induced gene expres-
sites of inflammation [2] and systemically within minutession of several cytokines, chemokines, and nitric oxide synthase-2
(NOS2), but the molecular mechanisms underlying these effects of endotoxin injection [3]. The therapeutic administration
have not been clearly defined. To test the hypothesis that a- of a-MSH has been shown to limit injury in experimental
MSH inhibits the expression of inducible trans-activating fac- models of sepsis and inflammatory or ischemic organ fail-tors involved in NOS2 regulation, we used RAW 264.7 macro-
ure [4–7], including ischemia-induced acute renal failurephage cells to examine the effects of a-MSH on the activation of
[8–10]. The salutary effects of a-MSH in these experimen-nuclear factor-kB (NF-kB) and CCAAT/enhancer binding
protein-b (C/EBPb), trans-acting factors known to be involved tal models appear to be in part attributable to its ability
in LPS 1 interferon (IFN)-g induction of the NOS2 gene. to limit induction of genes encoding proinflammatory cy-
Methods. Gel shift assays were performed to identify NF-kB tokines [tumor necrosis factor-a (TNF-a), interferon-g
and C/EBP DNA binding activities in LPS 1 IFN-g–treated
(IFN-g), and interleukin-1 (IL-1)] [6, 11, 12] chemokinesRAW 264.7 cells in the presence and absence of a-MSH. NOS2
(IL-8) [13], cell adhesion molecules (ICAM-1) [8], andpromoter assays were conducted to identify the effects of a-MSH
nitric oxide synthase-2 (NOS2) [5, 8]. By limiting theseon LPS 1 IFN-g–mediated induction of NOS2 transcription.
Results. Gel shift assays demonstrated LPS 1 IFN-g induction injury pathways, neutrophil infiltration, capillary conges-
of NF-kB and C/EBP family protein-DNA complexes in nuclei tion, and exposure of cell constituents to damaging reac-
harvested from the cells. Supershift assays revealed that the tive oxygen and nitrogen intermediates are reduced. InC/EBP complexes were comprised of C/EBPb, but not C/EBPa,
studies of a rodent model of bilateral renal ischemia/C/EBPd, or C/EBPe. a-MSH (100 nmol/L) inhibited the LPS 1
reperfusion injury, a-MSH abrogated renal injury [8, 10]IFN-g–mediated induction of nuclear DNA binding activity of
C/EBPb, but not that of NF-kB (in contrast to reports in other and preserved the glomerular filtration rate, tubular so-
cell types), as well as the activity of a murine NOS2 promoter- dium reabsorption [9], and urinary concentration [10].
luciferase construct. In contrast, a-MSH (100 nmol/L) had no The kidneys of the a-MSH–treated animals exhibited
effect on the induction of NOS2 promoter-luciferase genes har-
less neutrophil plugging, capillary congestion, tubular in-boring deletion or mutation of the C/EBP box.
jury, and protein nitrosylation, and negligible inductionConclusions. These data indicate that a-MSH inhibits the
of NOS2, cytokine-induced neutrophil chemoattractantinduction of C/EBPb DNA binding activity and that this effect
is a major mechanism by which a-MSH inhibits the transcription (KC)/IL-8, and the adhesion molecule ICAM-1 compared
of the NOS2 gene. The inability of a-MSH to inhibit LPS 1 with untreated controls [8]. The beneficial effect of a-MSH
IFN-g induction of NF-kB in murine macrophage cells, which in ischemia-reperfusion injury to the kidney is in part
contrasts with inhibitory effects of the neuropeptide in other cell
mediated by neutrophil-independent mechanisms sincetypes, suggests that cell-type–specific mechanisms are involved.
the protective effects of the peptide were observed in
ICAM-1 knockout mice, which exhibited 75% less neutro-
phil infiltration than background mice following renal is-Key words: a-malanocyte-stimulating hormone, transcription factors,
gene promoter, nitric oxide, lipopolysaccharide, interferon-g. chemia [9]. Consequently, a-MSH is being tested as a
candidate therapeutic agent for ischemic acute renal fail-Received for publication August 23, 1999
ure in humans.and in revised form December 11, 1999
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pletely defined. Such information is important, since the sion and several pleiotropic transcription factors are in-
duced during inflammation and ischemic injury, recentanti-inflammatory properties of the neuropeptide may
prove hazardous to immunocompromised patients, such attention has turned to the effects of a-MSH on inducible
transcription factors. Studies in various cell types (H4as those with multiple organ failure, who develop acute
renal failure. Macrophages represent the best studied cell and A-172 glioma cells, U-937 myeloid cells, Jurkat T cells),
and in animal models of brain inflammation showed thattype for modeling receptor-coupled signaling of a-MSH
and the ability of this peptide to influence the expression the neuropeptide inhibits NF-kB induction in response
to cytokines or LPS administration, at least in part byof macrophage gene products, including NOS2, that con-
tribute to inflammation and injury. It is known that cyto- preserving IkBa protein levels [28–32]. The effects of
a-MSH on NF-kB induction in macrophage cells, how-kines induce murine and human monocyte/macrophages
to secrete a-MSH and to up-regulate, in an autocrine man- ever, were not examined. In addition, since C/EBPb
trans-activates many of the same proinflammatory genesner, the expression of the melanocortin-1 receptor and
the pro-opiomelanocortin (POMC) precursor of a-MSH (for example, NOS2, ICAM-1 [33], monocyte chemoat-
tractant protein-1 [34], TNF-a [35], and IL-8 [13]) that[14, 15]. The increased production of a-MSH, in turn,
appears to inhibit NOS2 gene expression and limit NO a-MSH inhibits, we hypothesized that a-MSH might also
block the activation or action of C/EBPb. Using RAWproduction. Indeed, a-MSH limited TNF-a–mediated
induction of NOS2 mRNA levels and NO production in 264.7 macrophage cells as a model system, the present
results demonstrate a previously unrecognized action ofRAW 264.7 macrophages [15]. It was not determined,
however, whether this effect was the result of transcrip- a-MSH to inhibit the LPS 1 IFN-g–mediated induction
of C/EBPb-DNA binding activity and, as a consequence,tional repression of the NOS2 gene.
The NOS2 gene is typically quiescent in macrophages, the transcriptional activation of the NOS2 promoter. To
our knowledge, these data represent the first exampleas well as the majority of cell types, until transcriptionally
activated in response to bacterial lipopolysaccharide (LPS) of neuropeptide inhibition of NOS2 transcription, and
they suggest that C/EBPb inhibition is a central mecha-and/or certain cytokines [16]. The 59-flanking region of
the murine NOS2 gene contains multiple cis-elements nism by which a-MSH exerts its broad anti-inflammatory
actions and possibly its protective effects in ischemicthat bind trans-acting factors upon exposure to these
stimuli, including kB elements [17–19] and a CCAAT/ renal failure.
enhancer binding protein (EBP) box at nucleotide posi-
tions 2150 to 2142 [20] that have been shown to be
METHODS
functionally active and to mediate trans-activation of the
ReagentsNOS2 gene in LPS 1 IFN-g–treated cell types. The C/
EBP proteins comprise a five-member family of bZIP Lipopolysaccharide from E. coli serotype O11:B4 was
purchased from Sigma Chemical Co. (St. Louis, MO,(basic region leucine zipper) transcription factors that
regulate the expression of genes involved in diverse pro- USA). Mouse recombinant IFN-g was from Genzyme
(Cambridge, MA, USA), and a-MSH was from Phoenixcesses such as the acute phase response, inflammation,
cell growth, and differentiation [21–23]. C/EBPa, C/ Pharmaceuticals, Inc. (Mountain View, CA, USA). The
Dual Luciferasee reporter assay system, pGL3-Basic,EBPb, C/EBPg, C/EBPd, and C/EBPe trans-activate tar-
get genes, whereas CHOP and the alternative translation pRL-TK, and NF-kB consensus oligonucleotides were
obtained from Promega Corp. (Madison, WI, USA).products LIP and C/EBP-30 function as transcriptional
repressors [23]. Of these, C/EBPb and C/EBPd have [g-32P]-ATP, antirabbit and antimouse IgG conjugated
with horseradish peroxidase, enhanced chemilumines-been shown to be induced by LPS or cytokines. C/EBPb
is induced in kidneys from LPS-treated [22] or hypoxic cence (ECL)-Western blotting reagent, and poly (dI-dC)-
poly (dI-dC) were from Amersham-Pharmacia (Piscata-[24] mice [22], the kidneys of diabetic rats [25], the med-
ullary thick ascending limb (mTAL) of rats subjected to way, NJ, USA). Dulbecco’s modified Eagle’s medium
(DMEM), LipoFectamine Pluse reagent, and heat-inac-renal ischemia-reperfusion injury (abstract; Price et al,
J Am Soc Nephrol 6:987, 1995), as well as in several tivated fetal bovine serum (FBS) were obtained from
GIBCO/BRL (Althersburg, MO, USA). The BCA Pro-other cell types, including macrophages [26] and vascular
smooth muscle cells [27], which are subjected to immune tein Assay kit was from Pierce (Rockwood, IL, USA).
Antibodies to C/EBP family proteins and NF-kB p50,or hypoxic challenge.
The beneficial effects of a-MSH in diverse forms of as well as protein A/G PLUS-agarose, were purchased
from Santa Cruz Biotechnologies (Santa Cruz, CA, USA).inflammation and tissue ischemia, combined with a-MSH’s
ability to influence multiple proinflammatory genes, sug-
Plasmidsgest that it acts at common, early steps in the inflamma-
tory and injury cascades. Since transcription is the central The plasmids used in the present study have been
described in our earlier publication [20]: pNOS2-luc con-and initial control point for the regulation of gene expres-
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tains 1.6 kB of the 59-flanking region and 59-UTR of 10 mg nuclear extract protein with 1.75 pmol of [g-32P]-
ATP end-labeled C/EBP box DNA probe correspondingexon 1 (nucleotides 21486 to 1145) of the mouse NOS2
gene cloned into the HindIII and XhoI sites of pGL3- to the 2157 to 2136 of the murine NOS2 promoter (sense
strand, 59-CACAGAGTGATGTAATCAAGCA-39) inBasic; pNOS2-C/EBPdel-luc is identical to pNOS2-luc
except that the 2150 to 2142 C/EBP box in the NOS2 reaction buffer [25 mmol/L HEPES, pH 8.0, 50 mmol/L
KCl, 0.1 mmol/L EDTA, 1 mmol/L MgCl2, 1 mmol/Lpromoter was excised. pNOS2-DC/EBP-luc is identical
to pNOS2-luc except that the 2150 to 2142 C/EBP box DTT, 10% glycerol, and 50 mg/mL poly(dI-dC)-poly
(dI-dC)] for 30 minutes at room temperature [20]. Forin the NOS2 promoter contains a 6 bp mutation that
renders the C/EBP box incompetent to bind C/EBP pro- NF-kB EMSAs, 0.5 ng of [g-32P]-ATP end-labeled con-
sensus NF-kB probe (59-AGTTGAGGGGACTTTCCteins. Plasmid preparations were made using the endo-
toxin-free Plasmid Maxi-prep kit (Qiagen Inc., Santa CAGGC-39) were added to a 20 mL (final) reaction mix-
ture containing 10 mg nuclear extract in 10 mmol/L TrisClarita, CA, USA).
buffer (pH 7.5) with 50 mmol/L NaCl, 1 mmol/L DTT,
Cell culture 1 mmol/L EDTA, 5% glycerol, and 50 mg/mL of poly(dI-
dC)-poly (dI-dC)] for 20 minutes at room temperature.RAW 264.7 cells were obtained from American Type
Culture Collection (Rockville, MD, USA) and cultured in For competition studies, a 50-fold molar excess of specific
or heterologous (Oct-1) oligomer was included in thecomplete medium (DMEM supplemented with 2 mmol/L
l-glutamine, 100 U/mL penicillin, 100 U/mL streptomycin, binding reaction. For supershift assays, 1 mL (10 mg) of
IgG directed against C/EBPa, C/EBPb, C/EBPd, C/EBPe,and 10% FBS) at 378C in a humidified incubator with
5% CO2. Vehicle, LPS (100 ng/mL), IFN-g (0.5 U/mL), or NF-kB p50 was added to the binding mixture after
incubating with labeled probe. The mixture was furtherand/or a-MSH (100 nmol/L) were added to the cells as
indicated in the text and figure legends. This concentra- incubated for 30 minutes at room temperature. The
DNA-protein complexes were resolved on 5% polyacryl-tion of a-MSH was selected because it has been shown
to inhibit NOS2 mRNA expression in these cells [15]. amide gels in 0.5 3 Tris-Borate-EDTA buffer. The gels
were dried and exposed to x-ray film for autoradiography
Preparation of cytoplasmic and nuclear extracts to detect the shifted bands.
Cytoplasmic and nuclear extracts were prepared from
Immunoblot analysisRAW 264.7 cells treated with vehicle, a-MSH, LPS 1
IFN-g, or a-MSH 1 LPS 1 IFN-g, as detailed in our Twenty microgram samples of nuclear or cytoplasmic
extracts were diluted in electrophoresis sample buffer,earlier work [20]. Briefly, cells were washed twice with
phosphate-buffered saline (PBS), scraped from the dish, boiled for five minutes, and electrophoresed through
0.1% sodium dodecyl sulfate (SDS)-7.5% polyacryl-and pelleted. The cells were resuspended in CE buffer
[10 mmol/L Tris-Cl, pH 8.0, 60 mmol/L KCl, 1 mmol/L amide gels. The proteins were electrophoretically trans-
ferred to nitrocellulose membranes (Hybond ECL; Am-ethylenediaminetetraacetic acid (EDTA), 1 mmol/L di-
thiothreitol (DTT), 1 mmol/L phenylmethylsulfonyl fluo- ersham). Equality of sample loading and blotting was
verified by Ponceau S staining of the membranes. Theride (PMSF), and 0.1% NP-40] and were allowed to swell
on ice for 15 minutes. After brief vortexing, the lysed blots were first incubated in blocking solution (PBS con-
taining 1% bovine serum albumin and 0.1% Tween 20)cells were centrifuged at 3000 3 g for five minutes at 48C.
The resulting supernatant containing the cytosolic extract for one hour at room temperature and then in blocking
solution containing anti-C/EBPb antibody (5 mg/mL) forwas collected and stored at 2708C until further use. The
pellet containing the nuclear lysates was washed once one hour at room temperature. The blots were washed
extensively with a solution containing 10 mmol/L Tris,with CE buffer lacking NP-40, resuspended in NE buffer
(20 mmol/L Tris-Cl, pH 7.9, 1.5 mmol/L MgCl2, 0.2 mmol/L pH 7.5, 100 mmol/L NaCl, and 0.1% Tween 20. The
antigen-antibody complexes were detected by the en-EDTA, 420 mmol/L NaCl, 25% glycerol, and 0.5 mmol/L
PMSF), and mixed on an orbital shaker for 20 minutes hanced chemiluminescence protocol using horseradish
peroxidase-conjugated goat antirabbit IgG as secondaryat 48C. The nuclear lysates were then centrifuged at
12,000 3 g for 20 minutes at 48C, and the supernatant antibody.
containing the nuclear protein extract was collected and
Transient transfection of RAW 264.7 cells andstored at 2708C. Protein contents of the extracts were
reporter gene assaysassayed with the BCA-protein estimation kit.
RAW 264.7 cells grown in six-well plates were tran-
Electrophoretic mobility shift assays (EMSAs) and siently transfected with a total of 5 mg/well of plasmid
supershift assays DNAs using LipoFectamine Pluse reagent according
to the manufacturer’s protocol. pNOS2-luc, pNOS2-To identify C/EBP protein-DNA complexes, binding
reactions (20 mL total) were performed by incubating C/EBPdel-luc, pNOS2-DC/EBP-luc, or the parent vector
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pGL3-Basic, which lacks eukaryotic promoter and en-
hancer sequences, were added at 4.5 mg/well. For com-
parative purposes, the cells were cotransfected with the
Renilla luciferase expression plasmid with pRL-TK (0.5
mg/well) to control for transfection efficiency and other
assay-to-assay variability. Parametric studies (data not
shown) revealed that the promoter activity of the pRL-
TK plasmid was not affected by a-MSH or LPS 1 IFN-g.
Twenty-four hours after transfection, the medium was re-
placed with complete medium containing vehicle, a-MSH,
LPS 1 IFN-g, or a-MSH 1 LPS 1 IFN-g. Twenty-four
hours later, whole cell lysates were prepared using Pas-
sive Lysis Buffer (Promega) according to the manufac-
turer’s directions. Firefly and Renilla luciferase activities
in 100 mL lysate samples were measured in a Turner
Systems 20/20 luminometer using the Dual-Luciferasee
Reporter Assay System following the manufacturer’s
protocol. After background subtraction, firefly luciferase
activity was normalized for Renilla luciferase activity and
protein content of the lysates. The results were recorded
as “normalized NOS2 promoter activity.” Each experi-
mental observation represents the mean of duplicate de-
terminations.
Data analysis
Imaging and quantitation of bands were performed
using an image analysis system (Bio Image, Ann Arbor,
MI, USA). Quantitative data are presented as means 6
SE and were analyzed for statistical significance by analy-
sis of variance (ANOVA). P , 0.05 was considered sig-
nificant.
RESULTS
a-MSH inhibits induction of C/EBPb, but not NF-kB,
DNA binding activity in RAW 264.7 cells
Studies in a variety of cell lines have demonstrated
that LPS and/or cytokines induce nuclear activity of
C/EBPb. To determine whether induction of C/EBPb
also occurs in RAW 264.7 cells, nuclear extracts were
prepared from RAW 264.7 cells that had been treated
for four hours with vehicle or LPS 1 IFN-g, and EMSAs
with a double-stranded oligonucleotide probe corre-
sponding to the NOS2 promoter 2150 to 2142 C/EBP
box were performed. Four hours of induction was se- Fig. 1. Lipopolysaccharide (LPS) 1 interferon-g (IFN-g) promotes
increased C/enhancer binding protein b (EBPb) DNA binding activitylected because combinatorial interactions among trans-
in nuclear protein extracts of RAW 264.7 cells. (A) Nuclear proteinsacting factors are known to be important for transcrip-
extracted from RAW 264.7 cells that had been exposed to vehicle or
tional regulation of the NOS2 gene, and previous in vivo LPS (100 ng/mL) 1 IFN-g (0.5 U/mL) for four hours were subjected
to EMSA with a 32P-labeled oligomer containing the 2150 to 2142genomic footprinting studies in LPS-treated RAW 264.7
C/EBP box of the murine NOS2 promoter. To demonstrate bindingcells demonstrated that at least three hours of induction
specificity, reactions were also conducted in the presence of a 50-fold
are required for the full complement of inducible tran- molar excess of unlabeled C/EBP box oligomer (S) or heterologous (H)
oligomers (N 5 4). (B) Polyclonal IgGs specific for C/EBPa, C/EBPb,scription factors to bind to the murine NOS2 promoter/
C/EBPd, and C/EBPe and nuclear factor-kB (NF-kB) p50, p65, andenhancer region [36]. As seen in Figure 1A, LPS 1 IFN-g
c-Rel were used in supershift experiments with nuclear extracts from
induced sequence-specific DNA–protein interactions for LPS 1 IFN-g-treated (4 h) RAW 264.7 cells and the 32P-labeled murine
NOS2 C/EBP box oligomer (N 5 3).C/EBP proteins. Scanning densitometry of the C/EBP-
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specific protein-DNA complexes revealed an approxi- ments in protein abundance or nuclear translocation con-
tributed to the effects of a-MSH to inhibit C/EBPb DNAmate fourfold induction (control, 2.6 6 1.4 relative O.D.
units; LPS 1 IFN-g, 11.2 6 1.6 relative O.D. units; P , binding activity, immunoblot analysis was performed on
cytosolic and nuclear extracts prepared from RAW 264.70.05). Since all C/EBP family members a, b, d, g, and e
recognize the consensus sequence of the C/EBP box cells treated with LPS 1 IFN-g in the presence or ab-
sence of a-MSH. If a-MSH inhibited nuclear transloca-probe [23] and since C/EBPb has been shown to activate
NOS2 gene transcription [20, 37, 38], we used supershift tion of C/EBPb, more C/EBPb protein would be ob-
served in the cytosolic fraction and less in the nuclearassays with antisera for C/EBPa, C/EBPb, C/EBPd, and
C/EBPe to identify the C/EBP isoform(s) that contrib- fraction compared to controls. As depicted in Figure 3,
neither the relative abundance nor the relative ratios ofuted to the DNA-protein complex. Figure 1B demonstrates
that only the anti-C/EBPb IgG supershifted the C/EBP- C/EBPb in the nuclear and cytoplasmic extracts differed
between the two groups. Moreover, only the full-lengthDNA complex. These results indicated that C/EBPb was
the major, if not only, C/EBP isoform bound to the DNA C/EBPb protein was evident in the blots, indicating that
the internal splice variant LIP (for liver-enriched tran-probe. Similarly, since NF-kB p50 is known to hetero-
dimerize with C/EBPb in some cell types [39], we also scriptional inhibitory protein) is not expressed under
these conditions.sought to determine whether the C/EBP-DNA gel shift
complex included this protein. Supershift assays with the
a-MSH inhibits LPS 1 IFN-g induction of NOS2C/EBP box oligomer and antisera against CREB and
promoter activityNF-kB p50 showed no detectable supershift (Fig. 1B).
Thus, C/EBPb homodimers principally, if not exclu- Previous work demonstrated that RAW 264.7 cells
treated with a-MSH 1 LPS 1 IFN-g exhibited lowersively, bind to the 2150 to 2142 C/EBP box of the NOS2
promoter. steady-state levels of NOS2 mRNA compared with
LPS 1 IFN-g–treated controls [15]. However, it wasTo evaluate whether a-MSH could inhibit the induc-
tion of C/EBP-DNA binding activity, cells were treated not determined whether reduced rates of NOS2 gene
transcription accounted for the result. To determine di-for 12 hours with vehicle or a-MSH and were then stimu-
lated with LPS 1 IFN-g. a-MSH (100 nmol/L) dramati- rectly whether a-MSH inhibits the promoter activity of
the NOS2 gene, the effects of a-MSH on the LPS 1 IFN-gcally suppressed the LPS 1 IFN-g induction of C/EBP-
DNA binding activity (Fig. 2A, B). In contrast, direct inducibility of the NOS2 promoter-luciferase construct
pNOS2-luc transiently transfected into RAW 264.7 cellsaddition of a-MSH to the binding reaction had no effect
on C/EBP-DNA binding activity in the nuclear extracts were tested. We elected to assay promoter activities
rather than nuclear run-on transcription rates, becausefrom the LPS 1 IFN-g–treated cells (Fig. 2C), indicating
that intracellular signaling intermediates were required the former is more sensitive and quantifiable in detecting
changes in gene transcription. As expected from thefor the effect. Similar inhibitory effects on LPS 1 IFN-g
induction of C/EBP-DNA binding activity were observed work of others, NOS2 promoter activity was dramatically
stimulated by LPS 1 IFN-g in the vehicle-cotreated cellswhen a-MSH was given simultaneously with LPS 1 IFN-g
(N 5 3; data not shown). (Fig. 4) [18]. In the presence of a-MSH, however, LPS 1
IFN-g induction of NOS2 promoter activity was onlyNuclear factor-kB is known to be an important trans-
activator of the NOS2 gene in immune-activated RAW approximately 40% of that of the vehicle-cotreated cells,
indicating that a-MSH dramatically inhibited NOS2264.7 cells [17, 18], and its induction is known to be
inhibited by a-MSH in several cell types [28, 31, 32]. gene transcription. Moreover, a-MSH had no measur-
able effect on basal NOS2 promoter activity. In controlTherefore, we tested the effects of a-MSH on LPS 1
IFN-g–mediated induction of NF-kB in RAW 264.7 cells. experiments, none of these maneuvers had a significant
effect on the luciferase activity of the parent vectorFor cells treated with vehicle or a-MSH alone, a single
NF-kB protein DNA complex was observed. LPS 1 pGL3-Basic (Fig. 4).
IFN-g treatment induced two additional kB-specific
a-MSH inhibits LPS 1 IFN-g induction of NOS2complexes. a-MSH given 12 hours before or simultane-
promoter activity via a C/EBPb-dependent mechanismously with LPS 1 IFN-g had no significant effect on the
induction of NF-kB protein-DNA complexes in nuclei We previously demonstrated that the 2150 to 2142
C/EBP box of the murine NOS2 promoter is functionallyharvested from these cells (Fig. 2D).
important for trans-activation of the NOS2 gene in renal
a-MSH does not inhibit C/EBPb protein expression epithelial cells [20]. To determine whether similar events
or apparent nuclear translocation occur in murine macrophages, RAW 264.7 cells were
transfected with pNOS2-luc pNOS2-C/EBPdel-luc, whichThe short-term control of C/EBPb includes regulation
of translation [40], nuclear translocation [23], and phos- contains a mutated NOS2 promoter lacking the C/EBP
box, or pNOS2-DC/EBP-luc, which contains a mutatedphorylation state [41–43]. To determine whether decre-
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NOS2 promoter harboring a six-nucleotide mutation in
the C/EBP box. As shown in Figure 5, deletion or muta-
tion of the 2150 to 2142 C/EBP box reduced NOS2
promoter activity by roughly 60%, indicating that C/EBPb
contributes to trans-activation of the NOS2 gene in
RAW 264.7 cells, as has been reported in mTAL [20]
and mesangial cells [37].
Given the gel shift data demonstrating no effect of
a-MSH on induction of NF-kB (Fig. 2D), a-MSH would
be expected to have little inhibitory effect on the LPS 1
IFN-g inducibility of the NOS2 C/EBP mutation/dele-
tion promoter constructs if the ability of a-MSH to in-
hibit C/EBPb DNA-binding activity was the principal
mechanism by which the neuropeptide inhibited NOS2
promoter activity. Indeed, as shown in Figure 5, a-MSH
did not significantly alter the activity of pNOS2-C/EBPb-
del-luc or pNOS2-DC/EBPb-luc in LPS 1 IFN-g–treated
RAW 264.7 cells. Thus, the inhibitory effect of a-MSH
on NOS2 transcriptional activity under these conditions
appears to be principally the result of inhibition of
C/EBPb trans-activation of the NOS2 gene.
DISCUSSION
Using a murine macrophage cell line to dissect the
mechanisms by which a-MSH inhibits NOS2 gene ex-
pression, we discovered that this neuropeptide inhibits
LPS 1 IFN-g induction of C/EBPb DNA-binding activ-
ity and severely limits transcriptional activation of the
NOS2 gene by these stimuli. The parallel reductions
in C/EBPb-DNA binding activity (Fig. 2) and NOS2
promoter activity (Fig. 4), coupled with the failure of
a-MSH to inhibit LPS 1 IFN-g inducibility of nuclear
NF-kB DNA binding activity and of NOS2 promoter
constructs bearing a disrupted 2150 to 242 C/EBP box
(Fig. 5) strongly suggest that a-MSH inhibits C/EBPb-
mediated trans-activation of the NOS2 gene. These re-
sults extend mechanistically previous studies that dem-
onstrated an effect of a-MSH to limit the expression of Fig. 2. a-Melanocyte-stimulating hormone (a-MSH) inhibits the
steady-state levels of NOS2 mRNA in RAW 264.7 cells DNA-binding activity of C/EBPb, but not NF-kB, in nuclear protein
extracts of RAW 264.7 cells. (A) Nuclear proteins extracted from RAW[15], and to our knowledge, they represent the first con-
264.7 cells that had been exposed to vehicle, a-MSH, LPS 1 IFN-g, orfirmed example of peptide inhibition of NOS2 gene tran- LPS 1 IFN-g 1 a-MSH were subjected to EMSA with 32P-labeled
scription in mammalian cells. Since a-MSH did not affect oligomers for the 2150 to 2142 C/EBP box of the murine NOS2
promoter (N 5 5). In the representative autoradiograph shown, vehicleLPS 1 IFN-g–mediated induction of NF-kB in RAW
or a-MSH was given 12 hours before a 4-hour incubation with LPS 1264.7 cells, the effect of the neuropeptide on C/EBPb is IFN-g. Similar results were obtained when vehicle or a-MSH was given
not a generalized effect on inducible transcription fac- simultaneously with the LPS 1 IFN-g. (B) Histogram showing results
of densitometric analysis of EMSAs of experiments depicted in (A).tors. Our results also predict that a-MSH may inhibit
The relative O.D. of the C/EBP-specific bands are plotted. *P , 0.05
the induction of other C/EBPb-responsive genes, such vs. control (“a-MSH”). (C) Nuclear extracts were prepared from RAW
264.7 cells treated with LPS 1 IFN-g for four hours. EMSAs wereas cyclooxygenase-2 [44], CD11C/CD18 integrin [46],
performed by incubating the 32P-labeled C/EBP box oligomer and theIL-4 [47], IL-6 [48], macrophage inflammatory protein
nuclear extracts directly with 100 nmol/L a-MSH (N 5 4). (D) Nuclear
1a [49], involved in inflammation, injury, and immunity. extracts were prepared from RAW 264.7 cells treated with LPS 1 IFN-
g (L 1 I) for four hours. a-MSH (MSH, 100 nmol/L) was given eitherThe fact that the supershift with the anti-C/EBPb anti-
12 hours (212) before or simultaneously (0) with LPS 1 IFN-g. EMSAsbody was virtually complete (Fig. 1B), that antisera
were performed by incubating the 32P-labeled NF-kB consensus oligo-
against C/EBPa, C/EBPd, and C/EBPe failed to supershift mer with the nuclear extracts (N 5 2). Competition studies were per-
formed with a 50-fold molar excess of unlabeled NF-kB oligomer (S).the C/EBP box complexes (Fig. 1B), and that LIP protein
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Fig. 2. (Continued).
was not observed on immunoblots of nuclear extracts partitioning of C/EBPb protein in the cytoplasmic and
nuclear extracts (Fig. 3), it seems unlikely that the neuro-suggests that other C/EBP family members did not con-
tribute significantly to the DNA binding activity we mea- peptide exerts its actions by inhibiting C/EBPb protein
expression or nuclear translocation. Similarly, since wesured. The C/EBP proteins consist of an N-terminal
trans-activating domain, a basic DNA-binding region, did not observe LIP protein on immunoblots, a-MSH
does not up-regulate this transcriptional inhibitor. Weand a C-terminal leucine-zipper. Dimerization through
the leucine-zipper leads to formation of homodimers and conclude then that a-MSH must act at a more down-
stream mechanism(s) that impairs the DNA-binding ca-heterodimers, which then bind via their basic regions to
DNA sequences in the promoter/enhancer regions of a pacity of C/EBPb. The specific mechanism remains to be
defined. It should be noted, however, that our methodsvariety of genes, including acute phase response genes
in liver [50], cytokine genes in monocytes/macrophages did not allow us to distinguish a separate effect of a-MSH
to inhibit the transcriptional efficacy of C/EBPb. Phos-[35], and NOS2 in various cell types. Heterodimers
formed between C/EBPb and NF-kB p50 in vitro have phorylation by ras-dependent MAPKs [43], protein kin-
ase C [42], Ca21/calmodulin-dependent protein kinasebeen reported [39], but in supershift assays, we found
no evidence for NF-kB protein family immunoreactivity (CaMKII) [51], and certain oncogene kinases [52] is
known to enhance the trans-acting potential of C/EBPbin the C/EBP-specific complexes (Fig. 1B). Thus, the
observed protein-DNA complexes in RAW 264.7 cells in vitro. Similarly, phosphorylation by MAPKs and kinase
oncogenes neutralizes the inhibitory domains of C/EBPb,contained principally, if not exclusively, C/EBPb homo-
dimers. unmasking latent transcriptional efficacy of the factor
[52]. Further studies are needed to directly test the effectsThe short-term regulation of C/EBPb is complex and
incompletely defined, and includes controls of transla- of a-MSH on these pathways.
In contrast to reports in other cell lines [28, 31, 32]tion, phosphorylation state, interaction with regulatory
nuclear proteins, and transport to the target genes [23]. and brain tissue [29], in which cytokines or LPS were
used to provoke NF-kB activation, a-MSH did not in-The fact that a-MSH had no effect on C/EBPb-DNA
binding activity when added directly to the DNA-binding hibit LPS 1 IFN-g induction of NF-kB in the nucleus
of RAW 264.7 cells. The reasons for this difference arereaction (Fig. 2C) indicates that intracellular signaling
intermediates and mechanisms are required for the inhi- unclear and require further investigation. The activation
of NF-kB complexes is achieved through phosphoryla-bition of C/EBPb DNA-binding activity. Theoretically,
the inhibitory actions of a-MSH on C/EBPb-DNA bind- tion and subsequent polyubiquitination and degradation
of the inhibitory component IkB. The released NF-kBing activity and NOS2 trans-activation could arise from
reduced C/EBPb protein expression, impaired nuclear complexes then translocate to the nucleus where they
trans-activate target genes. One possibility is that a-MSHtranslocation, up-regulation of LIP, or a novel post-
translational mechanism that results in reduced DNA- fails to inhibit IkBa degradation in RAW 264.7 cells, as
it does in other cell types [28, 32], because of selectivebinding capacity of the transcription factor. Since a-MSH
altered neither the relative abundance nor the apparent effects on specific, and differentially expressed IkB ki-
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Fig. 4. a-MSH inhibits LPS 1 IFN-g–mediated activation of the NOS2
promoter. (A) RAW 264.7 cells were transiently cotransfected with
pNOS2-luc, containing the wild-type murine NOS2 promoter (h) or
the promoterless parent vector, pGL3-Basic together with pTK-RL (j;
to normalize for transfection efficiency). The transfected cells were
treated for 24 hours with LPS 1 IFN-g 1 vehicle or LPS 1 IFN-g 1
a-MSH given simultaneously. Firefly and Renilla luciferase activities in
lysates of the cells were then determined in a luminometer, normalized
to cell protein content, and reported as “normalized promoter activity.”
The mean (bars) 1 SE of four separate experiments is shown. *P ,
0.05 vs. vehicle-treated; #P , 0.05 vs. LPS 1 IFN-g treated; †P , 0.05Fig. 3. Effects of a-MSH on C/EBPb protein expression in cytosolic
vs. a-MSH treated.and nuclear extracts of LPS 1 IFN-g-treated RAW 264.7 cells. (A)
Immunoblots of nuclear and cytoplasmic extracts prepared from RAW
264.7 cells treated with LPS 1 IFN-g or LPS 1 IFN-g 1 a-MSH
were probed with anti-C/EBPb IgG and peroxidase-conjugated goat
antirabbit IgG. The a-MSH was given 12 hours before the 4-hour
incubation with LPS 1 IFN-g. Signal was detected by the ECL method.
(B) Densitometric analysis of immunoblots. The relative O.D. of the
C/EBPb bands are plotted (N 5 3). Symbols are: (h) vehicle; (j) a-MSH.
nases. Recent work in RAW 264.7 cells, for example,
identified a novel LPS-inducible IkB kinase, termed
IKK-i, that is differentially expressed among LPS-treated
cell types and tissues [53]. It is highly induced by LPS
in RAW 264.7 cells, spleen, and peripheral blood leuko-
cytes, but is only weakly induced in brain, a tissue in
which the inhibitory effects of a-MSH on the induction
of NF-kB have been observed [29]. It is also noteworthy
that Manna and Aggarwal observed significant differ-
ences among the cell types they tested in the ability of
Fig. 5. a-MSH inhibits LPS 1 IFN-g–mediated activation of the NOS2the neuropeptide to inhibit TNF-dependent induction of
promoter via a C/EBP-dependent mechanism. RAW 264.7 cells wereNF-kB [32]. a-MSH almost completely abolished NF-kB
transiently cotransfected with pTK-RL together with one of the follow-
induction in U-937, HeLa, and H4 glioma cells, but only ing three promoter-luciferase constructs: pNOS2-luc, pNOS2-C/EBP-
del-luc, containing a mutated NOS2 promoter lacking the 2150 to 2142partially inhibited NF-kB induction in Jurkat cells. In the
C/EBP box; or pNOS2-DC/EBP-luc, containing the NOS2 promoteraggregate, the existing data suggest that cell-type–specific bearing a six-nucleotide mutation in the 2150 to 2142 C/EBP box.
mechanisms define the molecular means by which a-MSH The transiently transfected cells were stimulated for 24 hours with
LPS 1 IFN-g 1 vehicle or LPS 1 IFN-g 1 a-MSH given simultaneously,elicits its anti-inflammatory actions.
and normalized promoter activity was measured (N 5 4). Symbols are:Our finding that a-MSH inhibits LPS 1 IFN-g induc- (h) vehicle; (j) a-MSH ; *P , 0.05 vs. pNOS2 transfected, LPS 1
IFN-g 1 vehicle treated.tion of NOS2 promoter activity establishes that a-MSH
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6. Rajora N, Boccoli G, Burns D, Sharma S, Catania AP, Liptonexerts major effects on transcription of the murine NOS2
JM: a-MSH modulates local and circulating tumor necrosis factor-
gene. Although the magnitude of the reduction in NOS2 a in experimental brain inflammation. J Neurosci 17:2181–2186,
1997promoter activity could solely account for the decre-
7. Rajora N, Boccoli G, Catania A, Lipton JM: a-MSH modulatesments in NOS2 mRNA levels observed by Star et al [15],
experimental inflammatory bowel disease. Peptides 18:381–385, 1997
further studies are required to test whether a-MSH also 8. Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, Star RA:
a-Melanocyte-stimulating hormone protects against renal injurydestabilizes NOS2 mRNA in RAW 264.7 cells. For ex-
after ischemia in mice and rats. J Clin Invest 99:1165–1172, 1997ample, Weisz et al reported that changes in both NOS2
9. Chiao H, Kohda Y, McLeroy P, Craig L, Linas S, Star RA: a-
gene transcription and mRNA half-life are important Melanocyte-stimulating hormone inhibits renal injury in the ab-
sence of neutrophils. Kidney Int 54:765–774, 1998determinants of the steady-state levels of NOS2 mRNA
10. Kwon T-H, Frokiaer J, Fernandez-Llama P, Knepper MA, Niel-in RAW 264.7 cells subjected to LPS 1 IFN-g treatment
sen S: Reduced abundance of aquaporins in rats with bilateral
[54]. While much is known about how NOS2 is transcrip- ischemia-induced acute renal failure: Prevention by a-MSH. Am
J Physiol 277(3 Pt 2):F413–F427, 1999tionally induced, very little is known about how the gene,
11. Taylor AW, Streilein JW, Cousins SW: a-Melanocyte stimulat-once stimulated, is inactivated. The present data, to-
ing hormone suppresses antigen stimulated T cell production of
gether with earlier work [15], disclose a host mechanism gamma interferon. Neuroimmunomodulation 1:188–194, 1994
12. Robertson BA, Gahring LC, Daynes RA: Neuropeptide regula-by which this endogenous neuropeptide can restrict or
tion of interleukin 1 activities: Capacity of alpha melanocyte stimu-terminate NO biosynthesis in activated macrophages.
lating hormone to inhibit interleukin 1 inducible responses in vivo
Such a mechanism might serve to preserve the functional and in vitro exhibits target cell selectivity. Inflammation 10:371–
385, 1986integrity of macrophages during the inflammatory re-
13. Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushimasponse, since high NO concentrations are known to be
K, Kishimoto T, Akira S: Transcription factors NF-IL6 and NF-kB
autotoxic to macrophages. Macrophages, then, have the synergistically activate transcription of the inflammatory cytokines,
interleukin-6 and interleukin-8. Proc Natl Acad Sci USA 90:10193–capacity to secrete under immune challenge two pep-
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14. Rajora N, Ceriani G, Catania A, Star RA, Murphy MT, Lipton
inhibit induction of NOS2 expression, apparently by tar- JM: a-MSH production, receptors, and influence on neopterin in
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1996gene activation. In addition, since macrophage infiltra-
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tion is a hallmark of ischemia-reperfusion injury to the JM: Evidence of autocrine modulation of macrophage nitric oxide
synthase by a-melanocyte-stimulating hormone. Proc Natl Acadkidney [56], the present results disclose a possible molec-
Sci USA 92:8016–8020, 1995ular mechanism by which a-MSH attenuates postische-
16. Kone BC: Nitric oxide in renal health and disease. Am J Kidney
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